Bayer/Onyx Kidney Cancer Drug NDA Will Wait For Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx says the results of the Phase II study for BAY 43-9006 are favorable and support its decision to proceed with its Phase III trial. Its partner, Bayer, previously said the filing could be based on Phase II results.